Full Text View
Tabular View
No Study Results Posted
Related Studies
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
This study is ongoing, but not recruiting participants.
Study NCT00439673   Information provided by Gruppo Italiano Malattie EMatologiche dell'Adulto
First Received: February 23, 2007   Last Updated: November 7, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Neoplasms
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
5-Azacytidine
Valproic Acid
ATRA
Additional drug interventions recognized in this trial
Azacitidine
More general drug interventions related to this trial
Anticonvulsants
Antimanic Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Gruppo Italiano Malattie EMatologiche dell'Adulto


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services